Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

 Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

Insights+ Exclusive: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic. The program features over 250 virtual oral abstract presentations and virtual 2,500 poster presentations in 24 disease-based and specialty tracks. In the 56th session of ASCO Virtual Science Program 2020 involved global companies with their prime focus in Oncology. Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased its leadership in lung cancer across early- and late-stage disease and reinforce its biomarker-driven approach. Our team at PharmaShots has summarized and complied the key events of ASCO 2020.

01. Roche to Present Results of Tiragolumab in P-II CITYSCAPE Study for Non-Small Cell Lung Cancer at ASCO20 #ASCO20

Date- May 14, 2020

Products- Tiragolumab

02.  AstraZeneca Reports Results of Tagrisso (osimertinib) in P-III ADAURA Study for EGFR-Mutated Lung Cancer #ASCO20

Date- May 28, 2019

Products- Tagrisso

03. AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20

Date- May 28, 2019

Products- Enhertu

04. Blueprint Medicines Highlights Durable Clinical Activity and Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors at ASCO #ASCO20

Date- May 28, 2019

Products- Pralsetinib

05. Merck’s Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20

Date- May 28, 2020

Products- Keytruda

06. Forma Therapeutics Highlights Clinical Data of Olutasidenib At ASCO20 Virtual Scientific Program

Date- May 28, 2020

Product- Olutasidenib

07. Ziopharm Reports Updated Results of Ad-RTS-hIL-12 + Veledimex for Recurrent Glioblastoma  #ASCO20

Date- May 28, 2020

Products- Ad-RTS-hIL-12, Veledimex

08.  Merck KGaA and Pfizer’s Bavencio (avelumab) Demonstrates the Potential in Gestational Trophoblastic Tumors #ASCO20

Date- May 28, 2020

Products- Bavencio

09. Adaptimmune Reports Clinical Update of ADP-A2M4 for Multiple Cancer Indication ASCO20 #ASCO20

Date- May 29, 2020

Products- ADP-A2M4

10. Nanobiotix Reports First Results of NBTXR3 in P-I Expansion Study for Locally Advanced Head and Neck Cancer #ASCO20

Date- May 29, 2020

Products- NBTXR3

11. Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma #ASCO20

Date- May 29, 2020

Products- N/A

12. Iovance Reports Updated Clinical Data of Lifileucel in C-144-01 Study for Advanced Melanoma #ASCO20

Date- May 29, 2020

Products- Lifileucel

13. AVEO Oncology Reports Overall Survival Results of Tivozanib in P-III TIVO-3 Study and Submitted NDA to the US FDA #ASCO20

 Date- May 29, 2020

Products- Tivozanib

14. Autolus Therapeutics Reports Additional Data of AUTO3 in P-I/II ALEXANDER Study for R/R Diffuse Large B Cell Lymphoma # ASCO20

Date- May 29, 2020

Products- AUTO3

15. Cardiff Oncology Data Reports the Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer #ASCO20

Date- May 29, 2020

Products- Onvansertib

16. Trillium Therapeutics Provides Update on the P-I Dose Escalation Study of TTI-622 #ASCO20

Date- May 29, 2020

Products- TTI-622

17. Immunogen Presents Initial Data of Mirvetuximab Soravtansine + Avastin in FORWARD II Study for Patients with Recurrent Ovarian Cancer Regardless of Platinum Status #ASCO20

 Date- May 29, 2020

Products- Mirvetuximab Soravtansine, Avastin

18. Heat Biologics Reports Positive Results of HS-110 + Nivolumab in P-II Study for Lung Cancer Trial #ASCO20

Date- May 29, 2020

Products- HS-110, Nivolumab

19. Deciphera Reports Results of Qinlock (ripretinib) in P-III INVICTUS Study for Patients with 4L Advanced GIST #ASCO20

Date- May 29, 2020

Products- Qinlock

20. Deciphera Reports Preliminary Data of Rebastinib in Combination with Paclitaxel in P-Ib/II Study for Patients with Advanced Endometrial Cancer #ASCO20

Date- May 29, 2020

Products- Rebastinib

21. Kura Oncology Reports OS Data of Tipifarnib in P-II Study for HRAS Mutant Head and Neck Squamous Cell Carcinoma

Date- May 29, 2020

Products- Tipifarnib

22. Silverback Therapeutics Reports Preclinical Data of SBT6050 as a Single Agent and in Combination with Trastuzumab to Treat HER2-Expressing Malignancies #ASCO20

Date- May 29, 2020

Products- SBT6050, Trastuzumab

23. Seattle Genetics Report Updated Results of Tukysa (tucatinib) in HER2CLIMB Study for Patients with HER2-Positive Breast Cancer with Stable or Active Brain Metastases #ASCO20

Date- May 29, 2020

Products- Tukysa

24. Gossamer Bio Reports Safety and Biomarker Data of GB1275 in P-I/II KEYNOTE-A36 Study for Selected Solid Tumors

Date- May 29, 2020

Products- GB1275

25. AstraZeneca and Daiichi Sankyo Report Results of Enhertu (trastuzumab deruxtecan) in P-II DESTINY-Gastric01 Study for HER2+ Metastatic Gastric Cancer #ASCO20

Date- May 29, 2020

Products- Enhertu

26. Athenex Reports Interim Data of Oral Paclitaxel P-II Study for Cutaneous Angiosarcoma #ASCO20

Date- May 29, 2020

Products- Paclitaxel

27. Alligator Bioscience Reports Results of ATOR-1015 in P-I Study for Metastatic Cancer #ASCO20

Date- May 29, 2020

Products- ATOR-1015

28. Treos Bio Reports Positive Final Results of PolyPEPI1018 in P-I/II Study for Microsatellite Stable Metastatic Colorectal Cancer #ASCO20

Date- May 29, 2020

Products- PolyPEPI1018

29. Myovant Sciences Reports Positive Efficacy and CV Safety Data of Relugolix in P-III HERO Study for Advanced Prostate Cancer #ASCO20

Date- May 29, 2020

Products- Relugolix

30. Janssen Divulges its Oncology Portfolio and Pipeline of Cell Therapies at ASCO20 Virtual Scientific Program #ASCO20

Date- May 29, 2020

Products- JNJ-4528, Erleada, Amivantamab, Teclistamab

31. Roche Reports Results of Alecensa in P-III ALEX Study for ALK-Positive Non-Small Cell Lung Cancer #ASCO20

Date- May 29, 2020

Product- Alecensa

32. AstraZeneca Report Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer #ASCO20

Date- May 29, 2020

Product- Imfinzi

33. AstraZeneca Report Results of Imfinzi (durvalumab) + Tremelimumab in P-II Study 22 for Advanced Liver Cancer#ASCO20

Date- May 29, 2020

Products- Imfinzi, Tremelimumab

34. BeiGene Presents Data of Tislelizumab + CT to Treat of Patients with Advanced Squamous Non-Small Cell Lung Cancer at ASCO20 #ASCO20

Date- May 29, 2020

Product- Tislelizumab

35. Amgen Reports Clinical Data of AMG 510 in CodeBreaK 100 Study for Multiple Solid Tumors #ASCO20

Date- May 29, 2020

Product- AMG 510

36. Amphivena Reports Data from First-in-Human Study of AMV564 for Patients with Solid Tumor #ASCO 2020

Date- May 30, 2020

Products- AMV564

37. Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC Study for Chronic Myeloid Leukemia in the Chronic Phase at ASCO and EHA #ASCO20

Date- May 30, 2019

Products- Iclusig

38. Taiho Oncology Presents Data of Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at #ASCO20

Date- May 31, 2020

Product- Futibatinib

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post